Recombinant Human LILRB2/CD85d/ILT4 Fc Avi-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # AVI2078

Biotinylated
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
AVI2078-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Learn more about Avi-tag Biotinylated Proteins

Source

CHO

Accession #

NP_005865.3

Structure / Form

Biotinylated via Avi-tag.

Conjugate

Biotin

Applications

Bioactivity

View all LILRB2/CD85d/ILT4 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human LILRB2/CD85d/ILT4 protein
Human ILT4
(Gln22-His458)
Accession # NP_005865.3		 IEGRMD Human IgG1 Fc
(Pro 100-Lys 330)		 Avi-tag
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

No results obtained, Gln22 inferred from enzymatic pyroglutamate treatment revealing Thr23

Predicted Molecular Mass

76 kDa

SDS-PAGE

90-100 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human Angiopoietin-like Protein 2/ANGPTL2 C-Terminal Fragment  (Catalog # 9795-AN) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag (Catalog # AVI2078) binds with an ED50 of 10-80 ng/mL.

Scientific Data Images for Recombinant Human LILRB2/CD85d/ILT4 Fc Avi-tag Protein, CF

Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag Protein Binding Activity.

When Recombinant Human Angiopoietin‑like Protein 2/ANGPTL2 C-Terminal Fragment (9795-AN) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag (Catalog # AVI2078) binds with an ED50 of 10-80 ng/mL.

Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag Protein SDS-PAGE.

2 μg/lane of Biotinylated Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Avi-tag Protein (Catalog # AVI2078) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 90-100 kDa and 180-200 kDa, respectively.

Formulation, Preparation and Storage

AVI2078
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LILRB2/CD85d/ILT4

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1-3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5-9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by down-regulation of co‑stimulatory molecules (10, 11). ILT4 mediates tolerogenic DC‑induced CD4+ T cell energy in vitro and in vivo (10-12). Our Avi-tag Biotinylated human LILRB2/CD85d/ILT4 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References

  1. Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7. 
  2. Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317. 
  3. Hunt, J.S. et al. (2005) FASEB J. 19:681. 
  4. Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423. 
  5. Borges, L. et al. (1997) J. Immunol. 159:5192. 
  6. Colonna, M. et al. (1998) J. Immunol. 160:3096. 
  7. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
  8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
  9. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
  10. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
  11. Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
  12. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.

Long Name

Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 5

Alternate Names

CD85d, ILT4, LIR2, MIR10

Entrez Gene IDs

10288 (Human)

Gene Symbol

LILRB2

UniProt

NP_005865.3

Additional LILRB2/CD85d/ILT4 Products

Product Documents for Recombinant Human LILRB2/CD85d/ILT4 Fc Avi-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human LILRB2/CD85d/ILT4 Fc Avi-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.